News

Viyash Scientific Ltd share price softened by 1.19% to Rs 273.8. The Company`s net profit rose by 19.45% to Rs 79.29 crore, while revenue from operations slightly gained 2.87% to Rs 946.36 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has improved by 0.56% over last one week and heading higher by 13.27% in last one month while the market capitalization of Viyash Scientific Ltd has inched up 2.76% and 21.93% in the same period respectively. Profit before tax (PBT) of Viyash Scientific Ltd stood at Rs 112.41 crore in Q2 FY26, expanding by 132.54% year-on-year, and dropping 10.24% quarter-on-quarter. EBITDA came in at Rs 170 crore, rallying 51.94% YoY and easing 1.03% sequentially. Total expenses posted a minor rise of 4.22% to Rs 829.75 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 402.34 crore, going up by 10.56% YoY, while employee benefits expense was at Rs 162.65 crore, rising by 8.56% YoY. For the TTM ended FY26, revenue from operations grew 13.75% to Rs 3420.31 crore, while net profit surged by 1324.54% to Rs 224.65 crore, compared to previous TTM. EBITDA jumped by 34797% to Rs 608.98 crore, and PBT jumped 2548.10% to Rs 349.02 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 322.91 crore in FY26, as against Rs 344.8 crore in FY25. Viyash Scientific Ltd soared by 54.86% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.56% during the same period.

Viyash Scientific will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Viyash Scientific announced that the 41th Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Viyash Scientific (Viyash), through its wholly owned subsidiary Alivira Animal Health (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of Rs 188 crore is expected to close in Q2 FY27. The transaction represents a significant step in Viyash`s strategy to capitalize on the mega-trend of a growing Companion Animal Health Generics market. It expands Alivira`s global Companion Animal Health business and strengthens its presence in the European pet care market.

Net profit of Viyash Scientific rose 459.12% to Rs 52.11 crore in the quarter ended March 2026 as against Rs 9.32 crore during the previous quarter ended March 2025. Sales rose 129.02% to Rs 919.96 crore in the quarter ended March 2026 as against Rs 401.70 crore during the previous quarter ended March 2025.For the full year,net profit rose 663.48% to Rs 177.28 crore in the year ended March 2026 as against Rs 23.22 crore during the previous year ended March 2025. Sales rose 13.75% to Rs 3420.31 crore in the year ended March 2026 as against Rs 3006.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales919.96401.70 129 3420.313006.84 14 OPM %20.0311.51 -19.0812.87 - PBDT185.6532.77 467 626.87333.45 88 PBT125.2416.65 652 393.2394.74 315 NP52.119.32 459 177.2823.22 663 Powered by Capital Market - Live News